LIBTAYO (cemiplimab-rwlc)- Squamous Cell Carcinoma- Basal Cell Carcinoma- Non small Lung Cancer

FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for patients with locally advanced or met...Подробнее

Neoadjuvant cemiplimab in patients with stage II-IV cutaneous squamous cell carcinomaПодробнее

Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell CarcinomaПодробнее

Frontline Libtayo Could Help Patients with Advanced Cutaneous Squamous Cell Carcinoma Avoid SurgeryПодробнее

Immunotherapy for Squamous Non-Small Cell Lung CancerПодробнее

Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell CarcinomaПодробнее

Cemiplimab in Managing Advanced cSCCПодробнее

Managing Patients on Immunotherapy in CSCCПодробнее

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCCПодробнее

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck Cutaneous Squamous Cell CarcinomaПодробнее

Patient Follow-Up After Receiving CemiplimabПодробнее

How Prevalent is Advanced CSCC?Подробнее

Squamous Lung Cancer, Part 4: ImmunotherapyПодробнее

Second-Line Systemic Treatment of BCCПодробнее

How Dangerous are Basal Cell Carcinoma and Squamous Cell CarcinomaПодробнее

[skin] Effects of cemiplimab used before skin cancer surgeryПодробнее

I-TACKLE: IO followed by cetuximab in la/metastatic cutaneous squamous cell carcinomasПодробнее

CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancerПодробнее

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinomaПодробнее